Mycophenolate Mofetil Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil is employed to modulate immune activity in several serious conditions.

• Organ transplant rejection: helps prevent graft rejection by suppressing the immune response.
• Lupus nephritis: reduces kidney inflammation and preserves renal function.
• Certain autoimmune diseases: controls disease activity by inhibiting lymphocyte proliferation.

• Mycophenolate Mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides. By blocking this pathway, the drug reduces guanosine triphosphate availability, selectively suppressing proliferation of activated T‑ and B‑lymphocytes and thereby dampening the adaptive immune response.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may affect hydration.
• Headache: occasional tension‑type headaches.
• Infections: increased susceptibility to common bacterial and viral infections.

Serious or Rare Side Effects

• Bone marrow suppression: anemia, leukopenia, or thrombocytopenia.
• Severe infections: opportunistic infections such as cytomegalovirus or Pneumocystis jirovecii pneumonia.
• Gastrointestinal ulceration or perforation.
• Hepatotoxicity: elevated liver enzymes or clinically significant liver injury.

Before initiating therapy, clinicians should evaluate several safety parameters.

• Monitor blood counts: regular CBC to detect bone marrow suppression.
• Assess renal function: dose may need adjustment in impaired kidneys.
• Screen for infections: evaluate for latent viral infections prior to treatment.
• Avoid in pregnancy: teratogenic; contraindicated in pregnant women.
• Counsel on contraception: effective birth control required during treatment.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Mycophenolate Mofetil can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce drug absorption.
• Live vaccines: increased risk of vaccine‑derived infection.
• Azathioprine: additive bone marrow suppression.
• Rituximab: enhanced overall immunosuppression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): increase plasma concentrations.
• CYP3A4 inducers (e.g., rifampin): decrease drug effectiveness.
• ACE inhibitors: may raise the risk of renal dysfunction when combined.